Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial — Deonna Ackermann (2021) | RDL Network
Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial
Article 2021 en
Authors
DA
Deonna Ackermann
AS
Amelia K. Smit
MJ
Monika Janda
Abstract
1 min read
Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12621000176864 . Registered on 18 February 2021.
Deonna Ackermann, Amelia K. Smit, Monika Janda, Cathelijne Van Kemenade, Mbathio Dieng, Rachael L. Morton, Robin Turner, Anne Ε. Cust, Les Irwig, Jolyn Hersch, Pascale Guitera, H. Peter Soyer, Victoria Mar, Robyn P.M. Saw, Donald E. Low, Cynthia Low, Dorothy Drabarek, D. Nicolás Espinoza, Jon Emery, Peter Murchie, John F. Thompson, Richard A Scolyer, Anthony Azzi, Alister Lilleyman, Katy Bell
William HK Schilling, Mavuto Mukaka, James J. Callery, Martin Llewelyn, Cintia Cruz, Mehul Dhorda, Thatsanun Ngernseng, Naomi Waithira, Maneerat Ekkapongpisit, James A Watson, Arjun Chandna, Erni Juwita Nelwan, Raph L Hamers, Anthony Etyang, M Beg, Samba O. Sow, William Yavo, Aurel Constant Allabi, Buddha Basnyat, Sanjib Kumar Sharma, Modupe Amofa-Sekyi, Paul Yonga, Amanda Adler,
Deonna Ackermann, Mbathio Dieng, Ellie Medcalf, Cathelijne H. van Kemenade, Marisa C. Jenkins, Monika Janda, Robin Turner, Anne Ε. Cust, Rachael L. Morton, Les Irwig, Pascale Guitera, H. Peter Soyer, Victoria Mar, Jolyn Hersch, Donald E. Low, Cynthia Low, Robyn P.M. Saw, Richard A Scolyer, Dorothy Drabarek, David Espinoza, Anthony Azzi, Alister Lilleyman,
Discussion(0)
No comments yet. Be the first to comment.